LI KANG BIOMEDICAL Co. Ltd. (6242) AI Stock Analysis

LI KANG BIOMEDICAL Co. Ltd.

(TPEx:6242)

Select Model

Rating:61Neutral

Price Target:TWD 33.00▼(-1.49% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by deteriorating free cash flow and weak technical momentum despite strong profitability, a conservative balance sheet, and attractive valuation. The stock appears fundamentally stable but carries meaningful cash-conversion and price-trend risks.

Positive Factors

Sustained High ProfitabilityPersistently high gross and EBIT margins indicate that the company has maintained meaningful profitability across multiple periods. This provides an internal cushion against moderate revenue volatility and can support reinvestment, dividends, and resilience over the next several quarters.

Negative Factors

Negative Free Cash FlowThe sharp move to negative free cash flow is a material pressure on financial quality because operating cash no longer covered investment or working-capital requirements. If sustained, it could reduce internally funded growth capacity and increase reliance on balance-sheet resources.

LI KANG BIOMEDICAL Co. Ltd. (6242) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.07B
Dividend Yield: 5.97%
Average Volume (3M): 5,211
Price to Earnings (P/E): 13.9
Beta (1Y): 0.25
Revenue Growth: -0.93%
EPS Growth: -10.65%
Country: TW
Employees: 130
Sector: General
Sector Strength: 55
Industry: Household & Personal Products

LI KANG BIOMEDICAL Co. Ltd. Business Overview & Revenue Model

Company Description

Li Kang Biomedical Co., Ltd. specializes in the development and distribution of nutritional supplements, cosmeceuticals, and health-focused beverages. Beyond its product lines, the company also provides consulting and operational support for tourism...

LI KANG BIOMEDICAL Co. Ltd. Financial Statement Overview

Summary

Strong profitability and a sound, low-leverage balance sheet are offset by sharply negative free cash flow, weaker cash conversion, and returns below prior-year levels.

Income Statement

76Positive

Balance Sheet

84Very Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	573.36M	589.21M	565.51M	629.38M	684.25M	386.97M
Gross Profit	385.44M	398.25M	386.10M	426.14M	388.58M	264.68M
EBITDA	92.45M	113.22M	112.16M	151.37M	152.07M	76.83M
Net Income	76.39M	83.82M	77.02M	110.99M	112.09M	51.44M
Balance Sheet
Total Assets	1.14B	1.09B	1.04B	827.00M	688.84M	616.07M
Cash, Cash Equivalents and Short-Term Investments	178.22M	190.22M	454.40M	301.02M	263.43M	175.75M
Total Debt	160.52M	148.39M	105.91M	101.44M	18.55M	41.34M
Total Liabilities	295.17M	221.82M	179.93M	196.97M	118.70M	124.07M
Stockholders Equity	842.86M	871.24M	855.68M	630.03M	570.14M	492.00M
Cash Flow
Free Cash Flow	-171.68M	-240.94M	654.00K	93.48M	154.54M	56.00M
Operating Cash Flow	82.06M	88.44M	65.38M	96.74M	157.24M	60.45M
Investing Cash Flow	-124.77M	-88.24M	-257.76M	-61.84M	-59.62M	12.20M
Financing Cash Flow	1.11M	-22.22M	145.48M	-55.07M	-66.97M	-69.39M

LI KANG BIOMEDICAL Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6242 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6242	61Neutral	TWD 1.07B	13.90	―	5.97%	-0.93%	-10.65%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4121	42Neutral	TWD 1.01B	-25.02	―	―	0.08%	-10.61%

* General Sector Average

Performance Comparison

TW:6242 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6242	LI KANG BIOMEDICAL Co. Ltd.	33.50	-3.41	-9.23%
TW:4121	Rossmax International Ltd.	12.25	-3.15	-20.45%
TW:6483	Original Biomedicals Co Ltd	14.80	4.85	48.74%
TW:6543	Perfect Medical Industry Co., Ltd.	16.55	-11.20	-40.36%
TW:6827	MegaPro Biomedical Co., Ltd.	15.30	-0.15	-0.97%
TW:7773	Fullhope Biomedical Co., Ltd	24.90	-9.55	-27.72%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

LI KANG BIOMEDICAL Co. Ltd. AI Stock Analysis